ProMIS Neurosciences, Inc. (PMN)
| Market Cap | 20.72M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -563,349 |
| Shares Out | 20.13M |
| EPS (ttm) | -0.03 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 52,394 |
| Open | 0.950 |
| Previous Close | 0.955 |
| Day's Range | 0.950 - 1.030 |
| 52-Week Range | 0.910 - 3.100 |
| Beta | 0.61 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 3, 2024 |
About PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers an... [Read more]
Financial Performance
Financial StatementsNews
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential...
ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer's disease patients pla...
ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody...
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeu...
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeut...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for potential Alzheimer's disease vaccine
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fl...
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as ...
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies Study results support differentiation of PMN310 from other amyloid-beta-directed antibodies
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
Study results support ProMIS' TDP-43 misfolding-specific epitope as a potential therapeutic target for Amyotrophic Lateral Sclerosis (ALS) Study results support ProMIS' TDP-43 misfolding-specific epit...
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeu...
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer's disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as ...
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
Adds Key U.S. and International Patent Allowances to Further Protect the Company's Monoclonal Antibody Therapeutic for the Treatment of Alzheimer's Disease Adds Key U.S. and International Patent Allow...
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of therapeut...
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson's disease and Dementia with Lewy bodies Lead vaccine candidate selected for advan...
ProMIS Neurosciences Issues Letter to Shareholders
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focus...
ProMIS Neurosciences, Inc. Announces Leadership Transition
Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer Appoints Neil Warma, Industry Leader and ProMIS Board Member, as Interim Chief Executive Officer
ProMIS Neurosciences Announces Publication on Novel Target for ALS
Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degenera...
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease
Advances novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ) in first-in-human study Advances novel monoclonal antibody designed to be highly selective f...
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
Raised $20.4 million in PIPE gross proceeds to support continued development of Company's PMN310 and novel antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
At-the-Market fundraise to support Company through several potentially value-creating milestones and beyond At-the-Market fundraise to support Company through several potentially value-creating milest...
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody...
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 21, 2023 (GLOBE NEWSWIRE) -- ProMIS Neuros...
ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights
Presented c ompelling preclinical data support ing therapeutic potential of PMN310 to treat Alzheimer's disease , and the promise of disease prevention with a computationally derived A lzheimer's dise...